Clinical Trials Browser

NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Phase 2 Recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Phase 2 Recruiting

314 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT07061964 2026-05-26

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

111 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07475403 2026-05-26

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Phase 2 Recruiting

53 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Phase 2 Recruiting

111 enrolled

EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT05616650 2026-05-22

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Phase 2 Recruiting

42 enrolled

Genitourinary

Prostatic Neoplasms

NCT06041503 2026-05-22

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Phase 2 Recruiting

68 enrolled

Genitourinary

Adenocarcinoma of the Bladder

NCT06770582 2026-05-22

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

160 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06842498 2026-05-22

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2 Recruiting

75 enrolled

Genitourinary

Prostatic Neoplasms

NCT07023432 2026-05-22

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Phase 2 Recruiting

78 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06053658 2026-05-20

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

48 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT06995677 2026-05-20

SURF302

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04346225 2026-05-19

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

Phase 2 Recruiting

75 enrolled

Genitourinary

Prostatic Neoplasms

NCT06503146 2026-05-19

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Phase 2 Recruiting

320 enrolled

CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT03933670 2026-05-18

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Phase 2 Recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT05951179 2026-05-18

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06533644 2026-05-18

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Recruiting

91 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06863311 2026-05-18

EXACT

Phase 2 Recruiting

70 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07285044 2026-05-18

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

27 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

200 enrolled

Genitourinary

Prostatic Neoplasms

NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

740 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06940518 2026-05-15

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 2 Recruiting

40 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

240 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Phase 2 Recruiting

12 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05168618 2026-05-14

AtezoCab

Phase 2 Recruiting

33 enrolled

Genitourinary

Prostatic Neoplasms

NCT06591650 2026-05-14

GCND

Phase 2 Recruiting

33 enrolled

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT06708949 2026-05-14

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase 2 Recruiting

15 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

36 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04981509 2026-05-13

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

65 enrolled

Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05169970 2026-05-13

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

Phase 2 Recruiting

215 enrolled

Genitourinary

Prostatic Neoplasms

NCT05239624 2026-05-13

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06022822 2026-05-13

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

Phase 2 Recruiting

90 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT07450599 2026-05-13

CHINANEO

Phase 2 Recruiting

250 enrolled

Genitourinary

High-Risk Localized Prostate Cancer

NCT07455903 2026-05-13

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Phase 2 Recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT05868265 2026-05-12

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Phase 2 Recruiting

24 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06852638 2026-05-12

CD70-targeted immunoPET Imaging of Malignant Cancers

Phase 2 Recruiting

300 enrolled

GenitourinaryHead & NeckLymphoid

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06111781 2026-05-11

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

Phase 2 Recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT07571551 2026-05-11

TRIPLE-PATH

Phase 2 Recruiting

75 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04986423 2026-05-08

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Phase 2 Recruiting

200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05155033 2026-05-08

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT05363280 2026-05-08

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Phase 2 Recruiting

80 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Small Cell Lung Carcinoma

NCT06632977 2026-05-08

PREDICT

Phase 2 Recruiting

474 enrolled

Genitourinary

Prostatic Neoplasms

NCT06733363 2026-05-08

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

344 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07087860 2026-05-08

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT07384416 2026-05-08

QL1706 Plus Lenvatinib in Previously Treated Penile Cancer

Phase 2 Recruiting

47 enrolled

Genitourinary

Penile Neoplasms

NCT03824652 2026-05-07

WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Phase 2 Recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT06290687 2026-05-07

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

Phase 2 Recruiting

40 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06760819 2026-05-07

panSOHO

Phase 2 Recruiting

111 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT05985161 2026-05-06

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Phase 2 Recruiting

45 enrolled

GenitourinarySarcoma

Wilms Tumor, Neurofibrosarcoma, Rhabdoid Tumor

NCT06822010 2026-05-06

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Phase 2 Recruiting

28 enrolled

Genitourinary

Urinary Bladder Neoplasms